The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms of inflating the price of insulin.The FTC on Friday filed an antitrust and consumer-protection lawsuit against the three largest pharmacy-benefit managers,

Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in exchange for keeping lower-cost insulin off their lists of approved